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OBJECTIVE—Atrial natriuretic peptide (ANP) regulates arte-
rial blood pressure. In addition, ANP has recently been shown
to promote human adipose tissue lipolysis through cGMP-
mediated hormone-sensitive lipase activation. We hypothe-
sized that ANP increases postprandial free fatty acid (FFA)
availability and energy expenditure while decreasing arterial
blood pressure.
RESEARCH DESIGN AND METHODS—We infused human
ANP (25 ng  kg
1  min
1) in 12 men (age 32  0.8 years, BMI
23.3  0.4 kg/m
2) before, during, and 2 h after ingestion of a
standardized high-fat test meal in a randomized, double-blind,
cross-over fashion. Cardiovascular changes were monitored
by continuous electrocardiogram and beat-by-beat blood pres-
sure recordings. Metabolism was monitored through venous
blood sampling, intramuscular and subcutaneous abdominal
adipose tissue microdialysis, and indirect calorimetry.
RESULTS—ANP infusion decreased mean arterial blood pres-
sure by 4 mmHg during the postprandial phase (P  0.01 vs.
placebo). At the same time, ANP induced lipolysis systemically
(P  0.05 vs. placebo) and locally in subcutaneous abdominal
adipose tissue (P  0.0001 vs. placebo), leading to a 50% increase
in venous glycerol (P  0.01) and FFA (P  0.05) concentrations
compared with placebo. The increase in FFA availability with
ANP was paralleled by a 15% increase in lipid oxidation rates
(P  0.05 vs. placebo), driving a substantial increase in postpran-
dial energy expenditure (P  0.05 vs. placebo).
CONCLUSIONS—Our data identify the ANP system as a novel
pathway regulating postprandial lipid oxidation, energy ex-
penditure, and concomitantly arterial blood pressure. The
ﬁndings could have therapeutic implications. Diabetes 57:
3199–3204, 2008
A
modest mismatch between energy intake and
expenditure elicits major changes in body
weight over years. Total daily energy expendi-
ture comprises resting metabolic rate, physical
activity, and postprandial thermogenesis. Measures that
increase postprandial thermogenesis could prevent or
treat obesity. Pharmacological strategies to augment en-
ergy expenditure have been unsuccessful because of side
effects (1). Manipulation of adrenergic transmission is
associated with increased thermogenesis, blood pressure
elevations, and other cardiac side effects (2). Atrial natri-
uretic peptide (ANP) has recently been shown to promote
adipose tissue lipolysis through cGMP-mediated, hor-
mone-sensitive lipase activation (3). ANP-mediated lipoly-
sis has only been observed in primates such as macaques
and humans but not in other species (4). ANP increases
circulating free fatty acid (FFA) levels in human subjects
(5–8). Previous studies with adrenergic agonists suggested
that increased circulating FFA concentrations can drive an
increase in energy expenditure (9). In our earlier studies,
ANP-mediated lipolysis did not alter energy expenditure in
the fasted state, whereas lipid oxidation rate increased
slightly (6,8). We now tested the hypothesis that ANP
augments postprandial FFA availability, lipid oxidation,
and energy expenditure while concomitantly decreasing
blood pressure in healthy young men.
RESEARCH DESIGN AND METHODS
We recruited 12 healthy, nonoverweight, nonobese individuals aged 32  0.8
years with BMI 23.3  0.4 kg/m
2. Subjects did not ingest any medication. The
institutional review board approved the studies, and written, informed con-
sent was obtained before enrollment.
Forty-eight hours before the experiment, volunteers were asked to abstain
from smoking, alcohol ingestion, caffeine-containing beverages, and vigorous
exercise. Subjects were studied twice on separate days in a randomized,
double-blind, placebo-controlled, and cross-over fashion. For that purpose, sub-
jects were randomized when to receive ANP or placebo by an automated
randomization program by a study nurse. On the study days, one of our
coworkers, who was not involved in the analysis of the data, prepared the
infusions. On one study day, subjects received an intravenous ANP (Clinalfa-
Bachem, La ¨ufelingen, Switzerland) infusion at a rate of 25 ng  kg
1  min
1.I n
previous studies, this dosage has been shown to yield venous ANP concentrations
that are within the physiological meaningful range (6,7). Normal saline solution
served as placebo. After 30 min of continuous infusion, subjects ingested a
standardized fat-rich test meal containing 45% fat, 40% carbohydrate, and 15%
protein. Infusions were continued for an additional 120 min after food intake.
Two subjects received an ANP infusion without a meal on a third study day.
Instrumentation. One catheter (Vasocan 20G; B. Braun, Melsungen, Ger-
many) each was placed into large antecubital veins of both arms. We used one
catheter for ANP infusion and the other one for blood sampling. A microdi-
alysis probe was inserted into abdominal subcutaneous adipose tissue and
another into skeletal muscle (quadriceps femoris and vastus lateralis). Oxygen
consumption and carbon dioxide production were measured by indirect
calorimetry using a ventilated hood (DeltatracII; Datex Ohmeda, Duisburg,
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DIABETES, VOL. 57, DECEMBER 2008 3199Germany) to assess energy expenditure and respiratory quotient and lipid
oxidation rates. Whole-body fat oxidation rates were calculated from each
period of gas collection and estimated using stoichiometric equations (10).
Heart rate was measured continuously by electrocardiogram (Cardioscreen;
Medis, Ilmenau, Germany). Beat-by-beat blood pressure (Finapres; Ohmeda,
Amsterdam, the Netherlands) and brachial arterial blood pressure (Dinamap;
Critikon) were determined.
Microdialysis. Details of the microdialysis technique were described previ-
ously (11,12). Brieﬂy, before insertion of the probes, we applied a local
anesthetic (lidocaine) either as a cream for adipose tissue (EMLA, Astra,
Germany) or as a subcutaneous injection for muscle (Xylocitin 1%; Jenap-
harm, Jena, Germany). After probe insertion, we started the tissue perfusion
with lactate-free Ringer solution (Serumwerk, Bernburg, Germany) at a ﬂow
rate of 2 l/min. The solution was supplemented with 50 mmol/l ethanol (B.
Braun, Melsungen, Germany) for blood ﬂow determinations. CMA/60 micro-
dialysis catheters and CMA/102 microdialysis pumps (both from CMA Micro-
dialysis, Solna, Sweden) were used. A 60-min period was allowed for tissue
recovery and for baseline calibration before ANP infusion. Two 15-min
dialysate fractions were collected at baseline.
Analytical methods. ANP concentrations were determined using a radioim-
munoassay (Peninsula Laboratories, San Carlos, CA), and venous glycerol
concentrations were determined with an ultrasensitive radiometric method
(13). Venous FFAs were assayed with an enzymatic method (Wako kit;
Unipath, Dardilly, France). Catecholamines were collected in EGTA tubes
(Kabevette; Kabe Labortechnik, Nu ¨mbrecht-Elsenroth, Germany) and pro-
cessed immediately in a refrigerated centrifuge. The plasma was stored at
80°C until analysis. Plasma epinephrine and norepinephrine were assayed
by high-pressure liquid chromatography with electrochemical (amperometric)
detection (14). Plasma renin concentration was measured by Immunoradio-
metric Assay provided by Cis Bio International (Gif-sur-Yvette, France).
Within- and between-run coefﬁcients of variation were 7.4 and 7.2% at 6.8
mU/l, 6.2 and 2.6% at 37.4 mU/l, and 1.3 and 4.7% at 217 mU/l. Reference values
are 7–75 mU/l. -Hydroxybutyrate was measured with an enzymatic method
(Wako kit; Unipath). Insulin concentrations were measured using a radioim-
munoassay (Sanoﬁ Diagnostics, Pasteur, France). Ethanol concentrations in
perfusate (inﬂow) and dialysate (outﬂow) were measured with a standard
enzymatic assay (15). Dialysate glucose, lactate, pyruvate, and glycerol
concentrations were measured with a CMA/600 analyzer (CMA Microdialysis).
Calculations and statistics. Changes in blood ﬂow were determined using
the ethanol dilution technique, which is based on Fick’s principle (16,17).
Accordingly, a decrease in the outﬂow-to-inﬂow ratio is equivalent to an
increase in blood ﬂow and vice versa. For simplicity, the term “ethanol ratio”
is substituted for the term “ethanol outﬂow-to-inﬂow ratio.” Changes in
glycerol concentration were used to assess changes in lipolysis and/or lipid
mobilization, and changes in glucose, lactate, and pyruvate concentrations
were used to assess changes in carbohydrate metabolism (18,19). In situ
recovery for glycerol, glucose, lactate, and pyruvate in the dialysate was
assessed by near-equilibrium dialysis (20). For all four metabolites, we found
recoveries of 30% in adipose tissue and 50% in skeletal muscle. All data are
expressed as means  SE. Two-way ANOVA testing was used to compare ANP
and placebo responses followed by Bonferroni post tests. In addition, we
determined changes from baseline for each intervention with one-way ANOVA
tests followed by Dunnett’s post test when the ANOVA P value was 0.05. A
value of P  0.05 was considered signiﬁcant.
RESULTS
ANP concentrations are within the clinically relevant
range. Baseline plasma ANP concentrations were 77  5
pg/ml with ANP and 63  8 pg/ml with placebo (NS vs.
placebo). With ANP infusion, ANP concentrations in-
creased fourfold (P  0.001 vs. placebo) throughout the
experiment, whereas ANP concentrations remained un-
changed with placebo (data not shown). In pathological
conditions, such as heart failure, plasma ANP concentra-
tions can exceed 500 pg/ml (21), suggesting that ANP
concentrations in our study were in a physiologically
meaningful range.
ANP infusion reduces postprandial blood pressure.
Blood pressure and heart rate responses after ingestion of
a standardized meal during placebo or ANP infusion are
illustrated in Fig. 1. Baseline mean arterial pressure was
80  2 mmHg before placebo and 81  2 mmHg before
ANP administration. Thirty minutes into the ANP infusion,
mean arterial pressure was 76  2 mmHg (P  0.01 vs.
placebo). Blood pressure increased acutely during meal
ingestion in both groups. In the postprandial phase, mean
arterial pressure was signiﬁcantly reduced with ANP infu-
sion compared with placebo (P  0.01, two-way ANOVA).
Heart rate increased with food ingestion and remained
elevated throughout the postprandial phase. The heart rate
increase was slightly greater with ANP. Baseline plasma
norepinephrine and epinephrine concentrations were
0.53  0.07 and 0.09  0.01 pmol/ml, respectively, with
placebo. With ANP, the values were 0.47  0.06 and 0.10 
0.01 pmol/ml, respectively (NS vs. placebo). At the end of
the postprandial phase, norepinephrine concentrations
with placebo were 0.56  0.06 compared with 0.73  0.12
pmol/ml with ANP (NS vs. placebo), and epinephrine
concentrations with placebo were 0.13  0.02 compared
with 0.21  0.07 pmol/ml (NS vs. placebo) with ANP.
Plasma renin concentration at baseline was 9.4  1.1 and
9.5  1.2 mU/l with ANP and placebo infusion, respec-
tively. Sixty minutes after the test meal, ANP decreased
renin concentrations by 30  5% (P  0.05 vs. placebo).
ANP increases systemic FFA availability. Figure 2
shows changes in venous insulin (Fig. 2A, left), glucose
(Fig. 2A, right), FFA (Fig. 2B, left), and glycerol (Fig. 2B,
right) concentrations after meal ingestion, with or without
ANP infusion. Fasting glucose concentration was 4.3 
0.16 mmol/l (78  2.8 mg/dl) before placebo infusion and
4.3  0.12 mmol/l (78  2.1 mg/dl) before ANP infusion
(NS vs. placebo). In the postprandial phase, venous glu-
cose concentration increased similarly with placebo or
ANP, reaching a maximum 30 min after the meal. Base-
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FIG. 1. Mean blood pressure (A) and heart rate (B) before and after
ingestion of a test meal. On one day, subjects ingested the meal during a
continuous ANP infusion; on another day, they ingested a meal during
placebo (PLC) infusion. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; a,
P < 0.05 ANP vs. placebo; b, P < 0.01 ANP vs. placebo. E, ANP; F, PLC.
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U/ml on the ANP and placebo infusion days, respectively.
The HOMA index, a surrogate for insulin sensitivity, was
0.68  0.1 and 0.69  0.1 on the ANP and placebo infusion
days, respectively. Even though glucose concentrations
throughout the study were similar, postprandial insulin
concentration was augmented with ANP. Glycerol was
produced during triglyceride hydrolysis. With placebo,
venous glycerol concentrations decreased sharply in the
postprandial phase. The phenomenon is explained by the
antilipolytic action of insulin. In contrast, with ANP, venous
glycerol remained elevated throughout the postprandial
phase compared with placebo even though insulin levels
were elevated. The observation suggests that ANP increased
lipolysis in the postprandial phase. Baseline FFA concentra-
tions were 315  33 mol/l on the ANP infusion day and
394  80 mol/l with placebo (NS). The ANP-mediated
increase in postprandial lipolysis resulted in increased sys-
temic FFA availability. We also tested the effect of ANP
infusion without a test meal in two subjects. FFA concentra-
tions were lowest during placebo with a test meal, higher
with ANP and a test meal, and even higher when ANP was
given without a meal (data not shown).
Contribution of adipose tissue to ANP-induced
changes in metabolism. We used microdialysis to follow
changes in adipose tissue and in skeletal muscle metabo-
lism. To monitor changes in blood ﬂow, we applied the
ethanol dilution technique (17). Adipose tissue ethanol
ratio was similar before placebo and before ANP infusion.
The ratio decreased with both ANP (P  0.05, one-way
ANOVA) and placebo (P  0.001, one-way ANOVA; data
not shown), suggesting an increase in local blood ﬂow
with both treatments. Microdialysate glycerol in adipose
tissue was increased with ANP but shows a two-phase
response with a decrease 60 min after meal ingestion and
an increase late into the postprandial phase (Fig. 3, top).
Because local blood ﬂow is increased in subcutaneous
adipose tissue with ANP, more substrate escapes from the
interstitial space. Therefore, the real increase in glycerol
with ANP might be even higher than the one we were able
to detect. With placebo, subcutaneous adipose tissue
glycerol concentrations slightly decreased after the test
meal (Fig. 3, top). In skeletal muscle, the ethanol ratio was
similar with ANP and placebo and did not change with
both treatments. Postprandial glycerol changes in skeletal
muscle decreased to the same extent with placebo or ANP
(Fig. 3, bottom).
ANP increases postprandial thermogenesis through
lipid oxidation. Figure 4 illustrates changes in energy
expenditure, relative lipid oxidation rates, and systemic
concentrations of the ketone body -hydroxybutyrate with
meal ingestion during placebo or ANP. With placebo,
energy expenditure increased substantially in the post-
prandial phase. The respiratory quotient did not change
with placebo, suggesting that the increase in energy ex-
penditure resulted from raised combined carbohydrate
and lipid oxidation. ANP augmented the postprandial
increase in energy expenditure. On ANP, the respiratory
quotient decreased from 0.771  0.016 at baseline to
0.735  0.018 30 min after the meal (P  0.05 compared
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FIG. 2. Venous insulin (A), glucose (B), FFAs (C), and glycerol (D) concentrations before and after ingestion of a high-fat test meal. On one day,
subjects ingested the meal during a continuous ANP infusion; on another day, they ingested a meal during placebo (PLC) infusion. *P < 0.05 vs.
baseline; **P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo. E, ANP; F, PLC.
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DIABETES, VOL. 57, DECEMBER 2008 3201with placebo). The decrease in the respiratory quotient
corresponds to an increase in lipid oxidation rate (P  0.05
compared with placebo; Fig. 4B) in subjects receiving ANP
infusions. -Hydroxybutyrate, a marker of hepatic lipid
oxidation, decreased slightly with placebo. With ANP,
-hydroxybutyrate concentrations increased threefold in
the postprandial phase (P  0.01 vs. placebo; Fig. 4C). The
area under the curve for the relative change in FFA
concentrations throughout the experiment inversely cor-
related with the area under the curve for relative respira-
tory quotient changes with ANP (r
2  0.44, P  0.05).
Taken together, our observations indicate that ANP is a
potent stimulator of postprandial lipid oxidation and en-
ergy expenditure and that the liver is a major organ of
ANP-induced lipid oxidation.
DISCUSSION
We identiﬁed the ANP system as a novel pathway that
regulates postprandial lipid oxidation. In particular, we
showed that ANP attenuates the postprandial decline in lipid
mobilization leading to increased FFAs, both before and after
ingestion of a standardized fat-rich test meal. The increase in
circulating FFAs was associated with increased lipid oxida-
tion driving an increase in postprandial energy expenditure.
ANP decreased blood pressure in the postprandial phase
with minimal reﬂex-mediated tachycardia.
The depressor response to ANP in our study can be
attributed to its well-established cardiovascular actions,
for example through modulation of the renin-angiotensin
system (22). ANP decreased postprandial renin concentra-
tions compared with placebo. Interestingly, the depressor
response to ANP was more pronounced late into the
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FIG. 3. Changes in microdialysis subcutaneous abdominal glycerol con-
centration (A) and skeletal muscle glycerol concentrations (B) before
and after ingestion after a test meal. On one day, subjects ingested the
meal during a continuous ANP infusion; on another day, they ingested a
meal during placebo (PLC) infusion. *P < 0.05 vs. baseline; **P < 0.01 vs.
baseline; a, P < 0.05 ANP vs. placebo. E, ANP; F, PLC.
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FIG. 4. Changes in energy expenditure (A) and lipid oxidation rates
(B) and relative changes in systemic -hydroxybutyrate concentra-
tions (C) with ANP or placebo (PLC) infusions. *P < 0.05 vs. baseline;
**P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo; b, P < 0.01 ANP vs.
placebo. E, ANP; F, PLC.
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the cardiovascular system to cope with postprandial vaso-
dilatation in the splanchnic tract (23). The mechanism
could contribute to postprandial hypotension in the el-
derly (23). Near complete adrenergic receptor blockade by
propranolol does not abrogate the metabolic actions of
ANP (5,7), suggesting that ANP-mediated metabolic effects
are not related to reﬂex-activated adrenergic stimulation.
Vasodilatation per se has not conclusively been shown to
affect lipolysis in the absence of release of a lipolytic
factor or withdrawal of antilipolytic mechanisms (24,25).
In accordance with previous studies (5–7,26), aug-
mented lipolysis with ANP resulted in a sustained increase
in circulating FFAs throughout the experiment. The obser-
vation suggests that the increase in FFA release was not
completely compensated by FFA re-esteriﬁcation or lipid
oxidation. Yet, compared with placebo, ANP induced an
increase in postprandial lipid oxidation rate. Plasma ke-
tone concentrations, which reﬂect hepatic lipid oxidation,
increased sharply with ANP infusion. Circulating free
carnitine concentrations have been reported to decrease
with ANP infusion (26). Carnitine is a critical factor for
fatty acid intramitochondrial transport by carnitine palmi-
tyl transferase I and thus -oxidation (27).
The mechanisms increasing lipid oxidation rate with
ANP are not fully understood. In human subjects, in-
creased lipolysis can drive an increase in lipid oxidation
rate. Systemic -1 and -2 adrenoreceptor agonist infu-
sions increase lipolysis and lipid oxidation rate (9). Lipol-
ysis inhibition with acipimox reduces adrenoreceptor-
mediated lipolysis and lipid oxidation. In the present study,
FFA concentrations were inversely correlated with the respi-
ratory quotient, suggesting that FFAs drive, at least in part,
the ANP-mediated increase in lipid oxidation rates. The
increase in FFAs may have led to secondary changes in
skeletal muscle metabolism (28). Increased postprandial
insulin with unchanged systemic and muscular glucose is
consistent with an ANP-induced state of insulin resistance
favoring lipid rather than glucose utilization. Perhaps ANP
also exerts a direct effect on fatty acid uptake and -oxida-
tion in peripheral tissues: ANP-induced lipolysis is mediated
by cGMP formation. Recently, cGMP has been shown to
increase mitochondrial biogenesis, ATP synthesis, and oxi-
dative phosphorylation in cultured myotubes (29). Chronic
inhibition of cGMP hydrolysis with a phosphodiesterase-5
inhibitor reduced weight and fat mass through increased
energy expenditure in high-fat–fed mice (30).
Increased lipolysis with ANP increased circulating FFA
levels throughout the experiment. Pancreatic -cells are
affected by FFAs depending on the duration of exposure.
Acutely, FFAs together with an increase in glucose concen-
trations induce an exaggerated insulin response (31). In
accord with previous studies (6,26), insulin concentrations
increased with ANP infusion in the early postprandial phase.
Insulin regulates lipolysis by modulating cAMP concentra-
tions through type 3B phosphodiesterase (PDE-3B).
ANP-induced lipolysis is mediated by cGMP formation.
Previously, radioligand binding assays using [
123I]-labeled
ANP as the ligand showed high-afﬁnity binding sites on
human adipocytes (32). ANP increased intracellular cGMP
concentrations 187-fold, whereas cAMP concentrations re-
mained unchanged. The increase in cGMP activates cGMP-
dependent protein kinase G, which phosphorylates and
activates hormone-sensitive lipase. In noncellular systems,
cGMP inhibits PDE-3B (33). However, pharmacological
PDE-3B inhibition or PDE-3B stimulation through insulin did
not affect ANP-induced lipolysis in isolated adipocytes
(32,34). In our study, the ANP-mediated lipolysis was atten-
uated early in the postprandial phase. In subcutaneous
adipose tissue, lipolysis decreased sharply after food inges-
tion and increased again late into the study. Lipolysis
inhibition coincided with the peak in circulating insulin
concentrations. This pattern might suggest a discrepancy
between in vitro and in vivo actions of ANP on metabolism.
ANP induced lipolysis in subcutaneous adipose tissue
but not in skeletal muscle. The molecular mechanism for
this difference is unknown. In skeletal muscle, only com-
bined hyperinsulinemia and hyperglycemia suppress lipo-
lytic activity (35). Lipoprotein lipase activity, which
hydrolyzes lipoproteins to FFAs and glycerol mainly in the
epithelium of capillary beds, is reduced by insulin in
skeletal muscle (36). However, consistent with the present
study, ANP did not increase glycerol concentrations in
skeletal muscle under basal conditions (6). This ﬁnding
argues against a speciﬁc insulin effect on the ANP-mediated
metabolic effect in skeletal muscle. The vastus lateralis
muscle consists of mixed muscle ﬁbers. Skeletal muscles
show different degrees of lipolytic response to adrenergic
stimuli according to their ﬁber type composition (37). In
contrast to adipose tissue, glycerol can be taken up and
reused in muscle after triglyceride hydrolysis. Postprandially,
the effect can account for up to 50% of the released glycerol
(38). Finally, increased blood ﬂow could possibly wash out
interstitial glycerol concentrations. We did not observe a
change in local skeletal muscle blood ﬂow with ANP. How-
ever, the ethanol ratio is a qualitative rather than quantitative
method of determining blood ﬂow and therefore not sensi-
tive toward minor changes in blood ﬂow (39). We cannot rule
out the possibility that we missed subtle changes in blood
ﬂow and lipolysis.
Together, our ﬁndings suggest that the natriuretic pep-
tide system is an important regulator of postprandial
metabolism. The system may be amenable to therapeutic
intervention. For example, neutral endopeptidase inhibi-
tors are in clinical development for the treatment of
arterial hypertension and heart failure (40). Neutral endo-
peptidase inhibition may promote lipid mobilization and
oxidation. Our ﬁndings may also be important in terms of
human pathophysiology, both in conditions associated
with increased ANP and with decreased ANP availability.
ANP availability is increased in heart failure. With induc-
tion of -adrenoreceptor blocker therapy, natriuretic pep-
tide release increases further (41). Possibly, increased
lipid mobilization through natriuretic peptides sustains
substrate supply to the failing heart (42). Cardiac cachexia
is a complication of heart failure that worsens prognosis.
The cause of cardiac cachexia is unknown. Our ﬁndings
suggest that increased ANP-mediated lipid mobilization
and oxidation could predispose to cardiac cachexia (43).
ANP availability is decreased in obesity and states of
insulin resistance presumably through upregulation of the
natriuretic peptide-C clearance receptor (44,45). BMI and
circulating ANP and BNP concentrations are inversely cor-
related (46). Reduced ANP availability may provide a patho-
physiological link between obesity and arterial hypertension
(44,46). The novel ﬁndings presented here could have thera-
peutic implications for both cachexia and obesity.
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